Galectin Therapeutics (GALT) Retained Earnings (2010 - 2026)

Galectin Therapeutics' Retained Earnings history runs 17 years deep, the most recent figure standing at -$437.6 million for Q1 2026.

• In Q1 2026, Retained Earnings fell 6.43% year-over-year to -$437.6 million; the TTM figure through Mar 2026 stood at -$437.6 million (down 6.43% YoY), while the FY2025 annual figure was -$432.5 million, down 7.71% from the prior year.
• Retained Earnings was -$437.6 million for Q1 2026 at Galectin Therapeutics, down from -$432.5 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of -$280.6 million in Q1 2022 to a low of -$437.6 million in Q1 2026.
• Historically, Retained Earnings has averaged -$364.2 million across 5 years, with a median of -$365.9 million in 2024.
• The sharpest annual moves came in 2023 and 2026: Retained Earnings dropped 15.21% in 2023, then fell 6.43% in 2026.
• A 5-year view of Retained Earnings shows it stood at -$309.6 million in 2022, then declined by 14.47% to -$354.4 million in 2023, then fell by 13.32% to -$401.6 million in 2024, then decreased by 7.71% to -$432.5 million in 2025, then slipped by 1.17% to -$437.6 million in 2026.
• The last three Retained Earnings figures came in at -$437.6 million (Q1 2026), -$432.5 million (Q4 2025), and -$427.0 million (Q3 2025), per Business Quant data.